At a glance
ClinicalIndex Comparison RecordN/ACompleted· 32,864 enrolled
Drug / intervention
Azvudine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Real-World Effectiveness and Safety of Oral Azvudine in Hospitalized Patients With COVID-19: A Multicenter, Retrospective, Cohort Study
The First Affiliated Hospital of Zhengzhou University·observational·Posted Apr 5, 2024·Updated Apr 5, 2024
In Brief
An observational study evaluating Azvudine and Paxlovid for COVID-19 and Azvudine. Completed, enrolled 32,864 participants across 1 site.
Detailed Summary
To establish a real-world clinical cohort and database of Azvudine in the treatment of SARS-CoV-2 infection, and to provide stable and reliable evidence for the clinical efficacy and safety evaluation of azvudine in the treatment of SARS-CoV-2 infection.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesChina
CollaboratorsHenan Provincial Chest Hospital, The Affiliated Infectious Disease Hospital of Zhengzhou University, The Fifth People's Hospital of Anyang, Shangqiu Municipal Hospital, Nanyang Central Hospital, Luoyang Central Hospital, Guangshan County People's Hospital, Fengqiu County People's Hospital
Timeline
N/ACompletedFinished
202420252026
Enrollment StartDec 2023
Primary CompletionJan 2024
Study CompletionMar 2024
First PostedApr 2024
TodayJul 2026
First PostedApr 5, 2024
Enrollment StartDec 5, 2023
Primary CompletionJan 15, 2024
Study CompletionMar 10, 2024
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 2.2 years ago
Interventions
Azvudinedrug
Antiviral drug
Paxloviddrug
Antiviral drug